Review Finds AI Drug Discovery Has Yet to Deliver Clear Clinical Impact Despite Heavy Investment

A new peer-reviewed review argues that artificial intelligence has not yet translated its drug-discovery promise into clear clinical results, despite billions of dollars in investment and rapid progress in preclinical tools. The finding sharpens a growing divide in biopharma: AI is helping researchers generate candidates and run faster early experiments, but it has not yet shown that those candidates can reliably survive human biology and late-stage trials.